[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616067":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":25,"locations":34,"responsibleParty":46,"collaborators":24,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":24,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":76,"whyStopped":24,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Benha University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Gastritis group","ACTIVE_COMPARATOR","All included patients were subjected to full history taking including age, sex, residence, present illness; onset, course and duration, abdominal pain, other associated symptoms and family history. Assessment of anthropometric measurement Patients' height and weight for age and BMI percentiles were checked according to Egyptian growth curves .\n\nAbdominal Ultrasonography upper GIT ENDOSCOPY miRNA gene expression",[13],"Diagnostic Test: miRNA gene expression",{"label":15,"type":16,"description":17,"interventionNames":18},"Control healthy group","PLACEBO_COMPARATOR","miRNA gene expression",[13],[20],{"type":21,"name":17,"description":22,"armGroupLabels":23,"otherNames":24},"DIAGNOSTIC_TEST","Gene expression was done by quantitative reverse transcription-polymerase chain reaction (qRT-PCR).\n\nParaffin-embedded biopsies were sectioned into 10-μm-thick slices, two of which were deposited into 1.5-ml microcentrifuge tubes and dewaxed via immersion in xylene at 50 °C, followed by absolute and 96% ethanol.\n\nExtraction of total RNA (including miRNA) was performed using the Qiagen RNeasyPlus Universal Mini Kit (Qiagen, Hilden, Germany) according to manufacturer's protocol. Briefly, the samples were homogenized in QIAzol Lysis Reagent using TissueRuptor. RNA was further precipitated with chloroform, mixed with 1.5 volumes of 100% of Ethanol and following precipitation and washing steps eluted in RNase-free water. The concentration of extracted RNA was assessed using UV-spectrophotometry. MiRNA expression was quantitatively evaluated using either the TaqMan miRNA assay (Applied Biosystems, CA, USA) or SYBR Green (RNU6b) method. Approximately 20 ng of total RNA were reverse tran",[15,9],null,[26,31],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"nashwa f mohamed, MD","CONTACT","00201013085679","nashwafarouk16@gmail.com",{"name":32,"role":28,"phone":24,"phoneExt":24,"email":33},"ola G behairy, MD","OLAPED99@YAHOO.COM",[35],{"facility":36,"status":24,"city":37,"state":24,"zip":24,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":24},"Faculty of Medicine Benha University","Banhā","Egypt","EG",{"type":41,"coordinates":42},"Point",[43,44],31.1842,30.45977,{"lat":44,"lon":43},{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","Nashwa farouk Mohamed","lecturer of pediatrics","100616067","mirna-in-pediatric-gastritis-100616067",false,"NCT07300787","miRNA in Pediatric Gastritis","Role of miRNA-155 and miRNA-204 in Pediatric Gastritis","microRNA","Inclusion Criteria:\n\nrecurrent abdominal pain warranting upper gastrointestinal endoscopy or gastroscopy including\n\n* peptic-like dyspepsia (identified by two or more symptoms such as periodic pain, pain relief with food or antacid, pre-meal or hunger-induced pain, nausea\u002Fvomiting, and nighttime pain),\n* dysmotility-like dyspepsia (characterized by abdominal distension, anorexia, weight loss, pain worsening with food\u002Fmilk, and belching),\n* and reflux-like dyspepsia (manifesting as heartburn, chest pain\n\nexclusion criteria:\n\n-patients with gastrointestinal disorders explaining abdominal pain (e.g., inflammatory bowel disease, celiac disease, functional abdominal pain)\n\n, -patients on proton pump inhibitors, as well as those with significant medical comorbidities.\n\nExclusion Criteria:\n\n\\-",true,"ALL","1 Year","18 Years",{"count":63,"type":64},100,"ESTIMATED","INTERVENTIONAL",[67],"NA","The goal of this clinical trial is to assess the differential expression of miR-155 and miRNA-204 in relation to gastritis, and assess their relation with the presence of H. pylori in children.",[70],"HELICOBACTER PYLORI INFECTIONS",[72,73,74,75],"miRNA-155","miRNA-204","gastritis","H.pylori","NOT_YET_RECRUITING","2025-12-18",{"date":79,"type":80},"2025-12-24","ACTUAL",{"date":82,"type":64},"2026-01-20",{"date":84,"type":64},"2026-06-01",{"name":5,"class":6},1]